19th Annual Superbugs & Superdrugs
March 20 - 21, 2017 - London UKSMi Group
tarri@smi-online.co.uk
Phone:2078276162
SMi presents the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20 -21 March in Central London. Expanding horizons on the growing threat of anti-microbial resistance (AMR) for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities. The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of speakers A must attend for both new and seasoned stakeholders involved in AMR and infectious disease, the industry’s premier event will provide a perfect platform for its growing "superbugs" community to network, exchange novel solutions and consolidate current strategies. FEATURED SPEAKERS: Sumathi Nambiar, Dir, Division of Anti-Infective Products, FDA Richard Bax, Senior Partner, TranScrip Lloyd Czaplewski, Dir, Chemical Biology Ventures Chris Houchens, Branch Chief, BARDA James Anderson, Head of Corporate Government Affairs, GSK Aileen Rubio, Head of Biology, Spero Therapeutics David Williams, CEO, Discuva Martin Everett, CSO, ANTABIO SAS Jean de Gunzburg, Scientific Director, Da Volterra William J Weiss, Dir, Pre-Clinical Services, UNT System College of Pharmacy AGENDA HIGHLIGHTS: EXCLUSIVE: Regulatory perspective on drug development by the Director of the FDA Antibiotics Division Latest developments in antimicrobial peptides and chemotherapy Comprehensive overview of government funding initiatives Updates on clinical progress Spotlight on animal models in drug discovery